IAS HIV Cure & Cancer Forum
22 & 23 July 2017 | Paris, France

In 2017, the Towards an HIV Cure initiative organized a 1.5-day HIV Cure & Cancer Forum on 22 & 23 July in Paris, immediately preceding the 9th IAS Conference on HIV Science (IAS 2017).

An evolution of the annual Towards an HIV Cure Symposia, the Forum focused specifically on the interface and similarities between HIV cure and cancer research, and sought to merge these two disciplines to accelerate the pace of discovery in HIV cure research.

The Forum was co-chaired by Prof. Françoise Barré-Sinoussi, Dr. Steven Deeks, Professor of Medicine at the University of California, San Francisco (UCSF), and Prof. Sharon Lewin, Director of the Doherty Institute for Infection and Immunity, University of Melbourne.

Forum Objectives

  • Accelerate research on immunotherapy and epigenetic modification as potential curative strategies;
  • Create an environment to foster collaborations and merge the HIV cure and cancer disciplines;
  • Provide an opportunity for the next generation of investigators to launch their careers through interaction and discussion with peers;
  • Promote increased investments in HIV cure research;
  • Provide a platform for information sharing, debate and network among peers.

2017 HIV Cure & Cancer Programme Committee

Symposium Logistics

  • Rosanne Lamplough

CME accreditation

The IAS HIV Cure & Cancer Forum, Paris, France, 22/07/2017-23/07/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s).  Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. For more information, please contact [email protected].

The EACCME event report can be found here.

With the support of

Forum material

  • Related documents
  • Day 1
  • Day 2
  • Poster exhibition
  • Multimedia
The abstracts presented at the IAS HIV Cure & Cancer Forum are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

Opening Session

Keynote Address: HIV/AIDS and Cancer cure: Is it the same battle?
Monsef Benkirane, Institute of Human Genetics, CNRS, France


Oral Abstract Session 1: Burden of Disease

Invited Speaker: Real time detection of viral replication kinetics: A tool to identify functional viral reservoirs
François Villinger, New Iberia Research Center, University of Lousianna at Lafayette, United States


Invited Speaker: Liquid Biopsies: Monitoring the Cancer Genome in Blood
Sarah-Jane Dawson, Peter MacCallum Cancer Centre, Australia


OA1-1: Impact of vorinostat treatment of non-Hodgkin's lymphoma on HIV-1 latent reservoir
Adam Capoferri, Johns Hopkins University School of Medicine, United States


OA1-2: Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression
Genevieve Martin, University of Oxford, United Kingdom


Oral Abstract Session 2: Epigenetic Control of HIV-1 Latency: From Molecular Targets to Cure Strategies

Invited Speaker: Chromatin dynamics – epigenetic parameters and cellular fate
Geneviève Almouzni, Institut Curie, France


Invited Speaker: Epigenetic control of HIV latency
Jonathan Karn, Case Western Reserve University, United States


OA2-1: Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1
Carine Van Lint, Université Libre de Bruxelles (ULB), Belgium

OA2-2: JAK inhibitors employ novel mechanisms to block reservoir seeding and HIV persistence
Christina Gavegnano, Emory University, United States


OA2-3: Small-Molecule Chemotherapeutic Drugs Reactivate HIV-1 via Non-Canonical Pathways and Modulate CD8 T cell response
Isa Munoz-Arias, University of California, San Francisco, United States


Oral Abstract Session 3: Immunology and Immunotherapy

Invited Speaker: Paradigm shift in cancer therapy: targeting immune cells rather than cancer cells
Aurélien Marabelle, Gustave Roussy, France


Invited Speaker: Epigenetic control of T cell memory differentiation
Sebastian Amigorena, Institut Curie, France

OA3-1: HIV reservoir dynamics and immune responses after anti-PD-1 therapy
Timothy J. Henrich, University of California, San Francisco, United States

OA3-2: PD-1 blockade in 12 HIV-infected patients with lung cancer
Brigitte Autran, APHP - Hôpital Pitié Salpêtrière, France


OA3-3: Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T-cells
Sharon Lewin, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Australia


Oral Abstract Session 4: Immune Modulation and HIV Infection

Invited Speaker: Tissue Inflammation profiles: lessons for HIV/SIV control
Michaela Muller-Trutwin, Institut Pasteur, France

Invited Speaker: Interferon epsilon regulation of mucosal immune response in infection and cancer
Paul Hertzog, Hudson Institute of Medical Research, Australia

OA4-1: Combined IL-21 and IFNα treatment limits residual inflammation, viral persistence and delays viral rebound in SIV-infected Rhesus macaques
Mirko Paiardini, Yerkes National Primate Research Center, Emory University, United States


OA4-2: Evaluation of Different Treg Depletion Approaches as Strategies for Improved SIV Reactivation and Clearance
Ranjit Sivanandham, Center for Vaccine Research, University of Pittsburgh, United States


The abstracts presented at the IAS HIV Cure & Cancer Forum are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

Oral Abstract Session 5: Gene Therapy

Invited Speaker: Fast generation of the T cell compartment by using a ligand of Notch: Possible application to HIV affected patients
Marina Cavazzana, Hôpital Necker, France


Invited Speaker: Designing CART cells for HIV : a link between cancer and infectious disease therapy
Larry Corey, Fred Hutchinson Cancer Research Center, United States


OA5-1: Achievement of full donor chimerism with episodes of alloreactivity contributes to reduce the HIV reservoir after allogenic stem cell transplantation
Maria Salgado, AIDS Research Institute, IrsiCaixa, Spain

Roundtable: Clinical Trial Design and Participation


Clinical Trial Design Considerations in HIV Remission Studies
Jinatanat Ananworanich, US Military HIV Research Program, United States


Perspectives On Participation & Recruitment in HIV Cure-Related Trials
Michael Louella, University of Washington AIDS Clinical Trials Unit, United States


Precision Medicine in Oncology Field: From the new early clinical trials to the new personalized combinations
Jean-Philippe Spano, Pitié-Salpêtrière University Hospital, France


Melanoma Insights
Gilliosa Spurrier, Mélanome France, France


Clinical Trial Design Considerations: Leveraging Cancer Immunotherapy Studies to Evaluate HIV Endpoints
Thomas Uldrick, Center for Cancer Research, NCI, United States


Closing Session

Closing Lecture: Antibodies for Tumor Immunotherapy (and HIV?)
Alan Korman, Bristol Myers Squibb, United States

IAS-ANRS Dominique Dormont Prize Ceremony


The abstracts presented at the IAS HIV Cure & Cancer Forum are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

P1: Outcomes of cervical cancer among HIV-infected and uninfected women treated at the Brazilian National Institute of Cancer (2001-2013)
Marcelo Soares, Programa de Oncovirologia, Instituto Nacional de Câncer, Brazil


P2: Generation of new model systems for HIV infection to explore epigenetic effects of HIV integration site choice
Ulrike Lange, Heinrich Pette Institute - Leibniz Institute for Experimental Virology, Germany

P3: HIV prevalence among patients from the Brazilian National Cancer Institute: a call for the relevance of HIV malignancies
Fabio Leal,Programa de Oncovirologia, Instituto Nacional de Câncer, Brazil

P4: New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells
Damian Purcell, Doherty Institue for Infection and Immunity, University of Melbourne, Australia

P5: Inhibition of HIV-1 gene transcription by KAP1: a new CTIP2 interactant
Amina Ait Ammar, Strasbourg University, France

P6: Epigenetic dysregulation of the major histocompatibility complex (MHC) region in HIV-infected children on early antiretroviral therapy
Stephanie Shiau, Columbia University, United States

P7: A single-cell method to detect early activation of the latent HIV provirus
Peter Svensson, Karolinska Institutet, Sweden

P8: Implication of the HIV-1 pol gene intragenic enhancer in myeloid-specific viral gene expression
Roxane Verdikt, Université Libre de Bruxelles (ULB), Belgium

P9: LEDGIN-mediated inhibition of the IN-LEDGF/p75 interaction reduces provirus reactivation from latency
Zeger Debyser, KU Leuven, Belgium

P10: Histone deacetylase inhibitors reduce proteins crucial to the elongation, splicing and nuclear export of HIV RNAs
Talia Mota, The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia

P11: Murine model to predict viral rebound in HIV+ allotransplanted subjects
Maria Salgado, AIDS Research Institute, IrsiCaixa, Spain

P12: The optimization of antiviral RNAs for Use in a gene therapy approach to cure HIV-1 infection
Olivier Del Corpo, Lady Davis Institute for Medical Research, McGill University, Canada

P13: HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption
Wen Shi Lee, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Australia

P14: Treatment with tyrosine kinase inhibitors make PBMCs from patients with chronic myeloid leukemia less susceptible to HIV-1 infection: control of CD4+ T cell activation to control HIV-1 replication
Mayte Coiras, Instituto de Salud Carlos III, Spain


P15: Pulmonary T-cells and HIV reservoirs in adults under suppressive ART
Mohammad-Ali Jenabian, University of Quebec at Montreal (UQAM), Canada

P16: A subset of bnAbs exhibit broad binding to primary CD4+ T-cells infected with reactivated reservoir HIV in vitro
Yanqin Ren, The George Washington University, United States

P17: Priming of tumor or HIV specific human CD8+ T-cells with superior functional properties using STING ligands
Victor Appay, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), France

P18: Expanded Clones in SIV-Infected Macaques on Antiretroviral Therapy Recapitulate Key Features of Expanded Clones in HIV Infection:  Implications for Evaluation of “HIV Cure” Interventions
Jeff Lifson, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, United States

P19: HIV-1 Nef enhances viral reactivation and downregulates HLA class I: a dual role in modulating immune-mediated clearance of reservoirs
Xiaomei Kuang, Simon Fraser University, Canada

P20: Rapid CTL recognition of HIV-1 latently infected cells depends on the levels of inducible viral reactivation and CTL activation status
Alba Ruiz, AIDS Research Institute, IrsiCaixa, Spain

P21: Patient-Derived HIV Reservoirs can be Stably Engrafted into NSG Mice and Reactivated by Latency-Reversing Agents in vivo
Adam Ward, The George Washington University, United States

P22: The HIV reservoir as a genetically heterogeneous archive of within-host viral evolution: implications for immunotherapeutic cure strategies
Bradley Jones, BC Centre for Excellence in HIV/AIDS, Canada

P23: Knockdown of CCR5 expression in antigen-specific cytotoxic CD4 T cells
John Zaunders, Kirby Institute, UNSW Sydney, Australia


P24: HIV-specific, Ex-Vivo Expanded T-Cell Therapy (HXTC) for HIV Clearance: Feasibility, Safety, and Efficacy
David Margolis, UNC HIV Cure Center, University of North Carolina at Chapel Hill, United States

P25: Estimating the Contribution of Proliferation to HIV-Infected Lymphocyte Persistence
Jeffrey Gerold, Harvard University, United States

P26: Toward an HIV Functional Cure with CAR-T Cells: Elucidating Mechanisms Underlying the Extremely High Potency of Bispecific Anti-HIV CARs Designed for Optimal Activity and Minimal Immunogenicity
Edward Berger, NIAID, NIH, United States

P27: HIV-associated gastrointestinal microbial dysbiosis influences the efficacy of anti-HIV immunity by immune checkpoint blockade
Ivo SahBandar, University of Hawaii, United States

P28: Optimized ART and alloBMT to reduce HIV reservoirs
Adam Capoferri, Johns Hopkins University School of Medicine, United States


P29: Impact of Adjunctive Metformin Therapy on T cell Exhaustion and Viral Persistence in a Clinical Trial of HIV Infected Adults on Suppressive ART
Glen Chew, University of Hawaii, United States

P30: Changes in expression of small non-coding RNA during HIV infection and latency in a CD4+ T cell model of HIV latency
Bonnie Howell, Merck & Co., United States

P31: High prevalence of CXCR4-using virus and low clonal expansion in infected naïve and central memory CD4+ T cells in individuals on ART
Michael Roche, Peter Doherty Institute for Infection & Immunology, University of Melbourne, Australia

P32: Plasmacytoid DCs control HIV latency in resting T-cells by type I IFNα
Paul Cameron, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Australia


P33: Experiences and expectations of participants completing HIV cure focused clinical trials
James McMahon, Alfred Hospital and Monash University, Australia